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RECOMBINANT MYCOBACTERIA
OVEREXPRESSING D-ALANINE LIGASE
GENE AND USES THEREFORE
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cell wall and act synergistically with other antimicrobial
agents (Rastogi et al., 1990). In the early 1970s, David
(1971) isolated and characterized step-wise DCS-resistant
M. tuberculosis mutants that showed either normal or
5 reduced cellular permeability to DCS and speculated that Alr
CROSS-REFERENCE TO RELATED
APPLICATIONS
plays only a minor role in the mechanism of action of DCS.
Mycobacterium smegmatis, a nonpathogenic species, is a
This application is related to U.S. Provisional Application
useful model to study drug resistance mechanisms in pathogenic mycobacteria, especially when conserved cellular
Ser. No. 601434,200, filed on Dec. 17, 2002, which is
incorporated herein by reference.
l o processes are involved (Reyrat and Kahn, 2001; Tyagi and
Sharma, 2002). Peteroy et al. (2000) described the isolation
STATEMENT REGARDING FEDERALLY
and characterization of an M. smegmatis mutant resistant to
SPONSORED RESEARCH OR DEVELOPMENT
both DCS and vancomycin though the molecular basis of the
resistance mechanism remains unknown. In previous studThe present invention was sponsored by the United States 1s ies, we identified a spontaneous DCS-resistant M. smegmatis
Department of Agriculture under USDA Cooperative State
mutant with a promoter-up mutation in the alr gene, resultResearch Service Project Grant No. NEB 14-108 and the
ing in the overproduction of the Alr enzyme (Caceres et al.,
National Institute of Health under contract number R 0 3
1997). Air was shown to be inhibited by DCS in a concenA1051 176-01. The government may have certain rights in
tration-dependent manner, and DCS resistance could be
the invention.
20 conferred to pathogenic mycobacteria carrying the M. smegmatis alr gene in a multicopy plasmid. In addition, DCS was
BACKGROUND OF THE INVENTION
shown to competitively inhibit the native Ddl enzyme from
M. tuberculosis (David et al., 1969). Belanger et al. (2000)
The present invention relates to recombinant mycobactereported the characterization of a temperature-sensitive M.
rial strains overexpressing essential biosynthetic enzymes of 25 smegmatis mutant with a single amino acid substitution in
pathogenic mycobacteria and to methods for using these
Ddl. The mutant was more susceptible to DCS, and the
strains. More specifically, the present invention relates to
temperature sensitivity phenotype was due to the decreased
recombinant mycobacteria strains overexpressing D-alanine
activity of the mutated enzyme.
ligase (Ddl) and the use of such strains in in vitro methods
Recently, we observed that M. smegmatis alr null mutants
for identifying antimycobacterial agents directed against 30 are not dependent on D-alanine for growth, suggesting the
Ddl.
existence of another pathway for D-alanine biosynthesis
The bacterial cell wall is an ideal target for drug design
(Chacon et al., 2002). In addition, the alr null mutant is
since similar structures and biosynthetic pathways are absent
hypersusceptible to DCS, suggesting that a lethal target
from mammalian hosts. The lipid-rich mycobacterial cell
other than Alr is responsible for the bactericidal effect of
wall acts as an efficient permeability barrier (Brennan and 35 DCS.
Nikaido, 1995). Peptidoglycan, the backbone of this strucIn order to develop novel antimicrobial agents structurally
ture, contains the D-amino acids D-alanine,D-glutamate, and
related to DCS, the lethal target(s) of DCS need to be
diaminopimelate, which may contribute to its stability
identified and methods of screening for inhibition need to be
against proteolytic degradation. D-Alanine is one of the
developed.
central molecules of the cross-linking step of peptidoglycan 40
BRIEF SUMMARY OF THE INVENTION
assembly. Peptidoglycan biosynthesis in mycobacteria follows pathways similar to those in other eubacteria (Belanger
In this study, we investigated the roles of both Alr and Ddl
and Inamine, 2000). There are three enzymes involved in the
in the mechanisms of action of and resistance to DCS in M.
D-alanine branch of peptidoglycan biosynthesis: the pyridoxal phosphate-dependent D-alanine racemase (Alr), the 45 smegmatis. We demonstrate that Ddl activity is inhibited by
ATP-dependent D-a1anine:o-alanine ligase (Ddl), and the
DCS in a concentration-dependent manner. Overexpression
ATP-dependent D-a1anine:o-alanine-adding
enzyme (MurF)
of the ddl gene confers resistance to DCS but not to
(Walsh, 1989). D-Cycloserine (DCS; 4-amino-3-isoxazolidi0-chloro-D-alanine (BCDA), an inhibitor of D-alanine racenone) is a rigid analog of D-alanine and targets both Alr and
mase. Furthermore, a strain overexpressing both the alr and
Ddl in Escherichia coli (Lambert and Neuhaus, 1992; Neu- 50 ddl genes displayed an increased level of resistance to DCS.
haus, 1967). DCS also inhibits Mycobacterium tuberculosis
Analysis of the intracellular alanine pools in wild-type and
Alr and Ddl enzymes (David et al., 1969; Strych et al.,
recombinant M. smegmatis strains demonstrated that Ddl
2001), suggesting that both Alr and Ddl are targets of DCS
activity is not significantly affected by DCS at concentrain mycobacteria.
tions inhibiting Alr.
The present invention is directed to recombinant mycoDCS is effective against mycobacteria and is recom- 55
bacterial strains which overproduce D-alanine ligase (Ddl),
mended to treat multidrug-resistant M. tuberculosis in the
to cloned isolated genes encoding Ddl, and to the uses of the
DOTS-Plus management plan (Farmer, 2001; World Health
recombinant strains, and heterologous proteins.
Organization, 2000). However, undesirable side effects
In one aspect of the present invention, recombinant M.
restrict its use in human chemotherapy (Yew et al., 1993).
Nonetheless, the potent bactericidal effect of DCS against 60 smegmatis strains expressing heterologous or overexpressmycobacteria makes this drug an attractive prototype coming native Ddl are provided. In one embodiment of this
pound to develop novel antimycobacterial agents. In addiaspect, the Ddl is the product of M. smegmatis ddl gene. In
tion, identification of the lethal target(s) of DCS action
another embodiment, the Ddl is the product of M. tubercuwould allow for the rational design of new antimycobactelosis ddl gene. In yet another embodiment, the Ddl is the
rial drugs, structurally related or unrelated to DCS, targeting 65 product of both M. smegmatis and M. tuberculosis ddl genes.
In another aspect of the invention, purified recombinant
enzymes of the D-alaninepathway of peptidoglycan biosynthesis. Moreover, these types of inhibitors may weaken the
Ddl is provided.
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In a further aspect of the invention, cell-free methods for
squares), GPM2 (open squares), GPM259 (open triangles),
GPM265 (solid triangles), GPM14 (solid diamonds), and
screening for antimicrobial agents which target the D-alanine
GPM260 (open diamonds). Statistical analysis for three
ligase, an enzyme in the D-alanine branch of mycobacterial
peptidoglycan synthesis are provided. In one embodiment of
independent experiments was performed as described in
this aspect, the antimicrobial agent is structurally related to 5 Materials and Methods. Susceptibilities to DCS can be
D-cycloserine. In another embodiment, the antimicrobial
divided into four groups (group I, mc2155 and GPM2; group
11, GPM259 and GPM265; group 111, GPM14; group IV,
agent is unrelated to DCS. In a further embodiment of this
aspect, the screening method employs a thin-layer chromaGPM260). Significant differences between groups were
tography assay to detect Ddl enzyme activity. In yet another
detected (group I versus group 11, Pe0.003; group I1 versus
embodiment, the screening method employs a phosphate 10 group 111, PP0.025; group I11 versus group IV, P=0.020),
release assay.
while no significant differences within groups were detected
(P20.881).
In another aspect of the invention, in vitro methods for
detecting bactericidal activity of compounds against pathoFIG. 6 shows characteristic HPLC chromatographic progenic mycobacteria are provided. The methods comprise the
files of M. smegmatis intracellular amino acid pools. Intrause of overexpressing recombinant mycobacterial strains In is cellular amino acid pools of M. smegmatis mc2155 untreated
one embodiment of this aspect, the recombinant mycobac(A) and treated with DCS (B) were prepared and analyzed
by a reverse-phase HPLC method as described in Materials
terial strain is GPM259. In another embodiment, the recombinant strain is GPM260. In a further embodiment, the
and Methods. The synthetic amino acid L-homo-arginine
(L-hArg) served as an internal standard for quantifying the
recombinant strain is GPM265.
20 abundance of each individual amino acid Peaks for various
BRIEF DESCRIPTION OF THE DRAWINGS
amino acids are indicated, with L- and D-alaninehighlighted.
FIG. 7 shows intracellular pool of alanine in M. smegFIG. 1 shows primer extension analysis of the M. smegmatis strains Exponentially growing MJ"smegmatis cells in
matis and M. tuberculosis ddl transcripts. Total RNA (40 pg)
minimal media were split into two subcultures, and DCS
from mc2155, GPM259, and GPM265 was annealed with 25 was added to a final concentration of 75 pg ml-' to one of
primer SMDDLPE (A) or TBDDLPE (B) and extended as
the subcultures Cells were harvested after 2 h of incubation,
described in Materials and Methods. Lanes A, C, G, and T
and intracellular amino acid pools were determined as
display a dideoxy sequencing ladder with the corresponding
described in Materials and Methods The intracellular pool of
primer. Asterisks, transcriptional start sites. The p u t a t i v e
alanine (full-length bars) is expressed relative to the
10 boxes are highlighted. The start codon (GTG) for the M. 30 L-glutamate pool ([AlaliL-Glu]). The relative abundance of
smegmatis ddl gene is boxed.
each stereoisomer in the pool is also shown by open (L-alaFIG. 2 shows autoradiograms of the TLC for typical Ddl
nine) and solid (D-alanine)bars and indicated in the table at
assays. Ddl activities in crude extracts were determined as
the bottom. Values shown are meanszstandard deviations of
described in Materials and Methods. (A) Linear increase in
three independent experiments. Analysis of variance was
the synthesis of the D-a1anine:o-alaninedipeptide at increas- 35 used to compare values for total alanine, L-alanine, and
ing amounts of GPM259 cell extract. The percentage of
D-alanine pools in each strain for both DCS-treated and
untreated cells. Significant differences were observed for the
conversion was defined as the percentage of the total radioactivity present in the [14c]o-~la:D-Ala dipeptide spot. (B)
L-alanine pools (P=0.03). For D-alanine pools, significant
Percent inhibition of dipeptide formation (percent inhibidifferences (asterisks) were observed only for strains
tionP1OO-100x[percent con~ersion,,~~
,&percent conver- 40 GPM259 (Pe0.05), GPM14 (Pe0.01), and GPM260
~ i o ~ , DCS])
~ ~ , in
, ~GPM259 cell extract (8 pg of total
(p<0.01).
protein) at increasing concentrations of DCS.
FIG. 3 shows analysis of Dir and Alr activities in M.
DETAILED DESCRIPTION OF PREFERRED
smegmatis strains. Specific activities for Ddl (A) andAlr (B)
EMBODIMENT
in crude extracts were determined as described in Materials 45
and Methods. Specific activities are expressed as microD-Cycloserine (DCS) targets the peptidoglycan biosynmoles of substrate (L-alanine for Alr enzyme assay and
thetic enzymes D-alanine racemase (Alr) and D-a1anine:oD-alanine for Ddl enzyme assay) per milligram per minute
alanine ligase (Ddl). Previously, we demonstrated that the
(meanszstandard deviations of triplicate measurements).
overproduction of Alr in Mycobacterium smegmatis deterFIG. 4 shows inhibitory effect of DCS on M. smegmatis 50 mines a DCS resistance phenotype. As described in further
Ddl activities. Enzyme activities were determined in cell
detail herein, we investigated the roles of both Alr and Ddl
crude extracts from mc2155 (solid squares), GPM14 (solid
in the mechanisms of action of and resistance to DCS in M.
triangles), GPM259 (open triangles), GPM260 (open
smegmatis. It was discovered that the overexpression of
either the M. smegmatis or the Mycobacterium tuberculosis
squares), and GPM265 (solid diamonds) in the presence of
increasing concentrations of DCS. Percent inhibition was 55 ddl gene in M. smegmatis confers resistance to DCS, but at
DcJSA,th,,t
lower levels than the overexpression of the alr gene. Furcalculated (percent inhibition=lOO-100[SA,,,
DCS]; SA, specific activity) from three independent experithermore, a strain overexpressing both the alr and ddl genes
ments. Statistical analysis was performed as described in
displayed an eightfold-higher level of resistance. The alaMaterials and Methods. The inhibition patterns can be
nine pools in M. smegmatis wild-type and recombinant
divided into two groups (group I, mc2155, GPM14, 60 strains with or without DCS treatment were determined.
GPM259, and GPM260; group 11, GPM265). A significant
Alr-overproducing strain GPM14 cells not exposed to DCS
difference between groups was detected (P=0.02), while no
displayed almost equimolar amounts of L- and D-alanine in
significant differences within group I were detected
the steady state. The wild-type strain and Ddl-overproducing
(P=0.28).
strains contained a twofold excess of L- over D-alanine.In all
FIG. 5 shows inhibition of colony formation by DCS for 65 strains, DCS treatment led to a significant accumulation of
L-alanine and a concomitant decease of D-alanine, with
various M. smegmatis strains. The curves were generated
from data of a representative experiment with mc2155 (solid
approximately a 20-fold excess of L-alanine in the Ddl-
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overproducing strains. These data suggest that Ddl is not
significantly inhibited by DCS at concentrations that inhibit
Alr. The present invention is based on the above discoveries
which suggest that Ddl is the lethal target of DCS and thus
allow for identification of novel drugs targeting the D-alanine
branch of mycobacterial peptidoglycan biosynthesis.
The publications and other materials used herein to illuminate the background of the invention, and in particular
cases, to provide additional details respecting the practice,
are incorporated by reference and for convenience are
referenced in the following text by author and date and are
listed alphabetically by author in the appended ~i~~ of
References.

These data confirmed that the mycobacterial Ddl enzyme is
a target of DCS.
~~~~~~~~~~~i~~
of either the M, smegmatis or M, tuberculosis ddl gene, using the same expression vectors as those
used to overexpress
(Caceres et al,, 1997), confers an
intermediate level of resistance to DCS. Furthermore,
GPM260, a recombinant strain of M. smegmatis overproducing both
and Ddl, was constructed and characterized'
a higher level resistance DCS than
GPM260
Its parent strain, GPM14, which is consistent with the
increased DCS resistance levels of S. gordonii mutants with
elevated Alr and Ddl activities (Reitz et al., 1967). To test the
hypothesis that inhibition of Alr by DCS decreases the
intracellular pool of D-alanine, we compared the levels of
D-alaninepools in wild-type and recombinant M. smegmatis
strains with or without DCS treatment. The results showed
that DCS treatment decreased the intracellular D-alanine
pools in strains with wild-type Alr activity while the Alroverproducing strain GPM14 maintained a relatively abundant pool of D-alanine. This observation is consistent with
the intermediate level of resistance to DCS of Ddl-overproducing strains. In addition, analysis of the alanine pools in
Alr-Ddl-overproducing strain GPM260 suggests that, upon
exposure to DCS, Alr is readily inhibited. In contrast,
overproduction of Alr andor Ddl does not have an effect on
the susceptibility to vancomycin. The increased resistance of
a previously isolated M. smegmatis mutant to both DCS and
vancomycin (Peteroy et al., 2000) may underscore a resistance mechanism different from overproduction of Alr a n d
Or Ddl. Regarding resistance to DCS, there has been only
one fully characterized mechanism in mycobacteria involving ~verex~ression
of the air gene (Caceres et al., 1997). In
this study, we have shown that overex~ressionof the ddl
gene also confers DCS resistance in M. smegmatis, but at
levels of resistance below those for strains overproducing
Alr. Therefore, we do not expect that mutational changes, for
example, ddl Promoter-up mutations, would play an important role in the emergence of naturally DCS-resistant strains.
The presence of a mutation(s) in the ddl structural gene
leading to DCS resistance has not been demonstrated and
needs further investigation.
DCS targets both Air and Ddl enzymes, but the lethal
target for its bactericidal effect has not been identified M,
smegmatis
null mutants are not dependent on D-alanine
for growth, indicating that there is another pathway for
D-alaninebiosynthesis (Chacon et al., 2002). In addition, the
M. smegmatis alr mutant is
DCS, underlying the existence of another lethal target, most likely Ddl.
The DCS hypersensitivity phenotype of the air mutant is
also consistent with the essentiality of the M. smegmatis ddl
gene, as s%gested by the temperature sensitivity phenotype
of a mutant carrying a single amino acid substitution in Ddl
(Belanger et al., 2000) This temperature-sensitive mutant is
also more susceptible to DCS, presumably due to the low
activity of the mutated Ddl. Therefore, Ddl seems to be the
lethal target of DCS, while the inhibition of Alr by DCS
further decreases the D-alanine pool and contributes to the
inhibition of Ddl. Previously, it was suggested that DCS
resistance in M. tuberculosis is primarily due to mutations in
the ddl gene (David et al., 1969), and it was further speculated that inhibition of Alr plays only a minor role in the
mechanism of DCS action (David, 1971) Contrary to this,
our data showed that Ddl is not significantly affected by
DCS at the concentration that inhibits Alr. Our observation
suggests that Alr overproduction contributes to the maintenance of the internal D-alanine pool, thus antagonizing the

DEFINITIONS
The present invention employs the following definitions:
"alrK and ‘‘air'' refer to the D-alanine racemase gene,
including normal alleles of the alrA gene.
"Air" and "Air" refer to o-alanine racemase enzyme.
''Displays increased susceptibility to antimycobacterial
agent" refers to a reduction in the minimal inhibitory concentration of the mutant strain when compared with the wild
type strain.
''DCS" and ''~-cycloserine" refer to 4-amino-3-isoxayolidinone.
"ddy refers to the o-alanine ligase gene including normal
alleles of the ddl gene.
"DdY refers to D-alanine-D-alaninesynthetase, which is
also referred to as D-alanine ligase.
"Isolatedpolypeptide" refers to a polypeptide produced as
an expression product of an isolated and manipulated
genetic sequence, even if expressed in a homologous cell
type. Synthetically made forms or molecules expressed by
heterologous cells are inherently isolated molecules.
previous studies, a genomic library from a DCSresistant mutant constructed in a multicopy plasmid was
introduced into the wild-type M. smegmatis strain and
clones resistant to 300 pg of DCS ml-' were selected and
isolated (Caceres et al., 1997). Using this strategy, we did
not identify a recombinant clone carrying the ddl gene. Since
target overproduction determines a drug resistance phenotype, this Outcome was
To
any possible
bias in this library, we also screened a M. smegmatis cosmid
library in a
manner.
a DCS resistant
clone carrying the ddl gene was still not identified. Lowering
the DCS concentration resulted in a high background of
DCS-sensitive colonies. These data suggest that either the
overexpression of the ddl gene is toxic to the host or that the
level of overexpression is not sufficientto confer a selectable
resistance phenotype under the selection conditions
described, T~ test these hypotheses, the M, smegmatis and
M. tuberculosis ddl genes were amplified from genomic
DNA and cloned into the E. c o ~ i - ~ y c o b a c t e ~ i ushuttle
m
vector pMV262, carrying a kanamycin resistance marker.
Recombinant plasmids were introduced into M. smegmatis,
and kanamycin-resistant transformants were isolated.
In this study, we demonstrated that Ddl enzyme activities
in crude extracts were inhibited by DCS in a concentrationdependent manner, similar to the effect observed for the Alr
enzyme (Caceres et al., 1997). Approximately 50% of Ddl
enzyme activity is inhibited by DCS at a concentration of
200 pg ml, while only 10 to 15% of the Ddl activity is
inhibited at 50 pg ml, near the MIC. The apparent discrepancy reflects the difference between in vivo and in vitro
conditions. In live bacilli, DCS also inhibits Alr, resulting in
a limited supply of D-Ala, which is the substrate for Ddl,
while in the cell-free assay, D-Ala is provided in excess.
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inhibition of Ddl by DCS. For the Streptococcus faecalis
lethal target of the bactericidal action of DCS. Thus, accordenzymes, the DCS inhibition constants for both Alr (Kr=0.02
ing to the present invention, a method is provided for
mM) and Ddl (Kr=0.9 mM) have been determined from the
screening of antimycobacterial agents against Ddl by a
variety of drug screening techniques.
purified enzymes (Neuhaus, 1967). If the K 3 for the mycoPreferably, purified Ddl is obtained from M. tuberculosis
bacterial enzymes were to follow a similar trend, an attrac- 5
tive hypothesis would be that the overproduction of a
ddl gene by PCR amplification and cloning into a proper
high-affinity DCS-binding target (Alr) would protect a more
expression shuttle plasmid vector, such as an E. coli expresfundamental and low-affinity target, probably Ddl, from
sion vector endowed with a mycobacterial replication origin
andor promoter, and overexpressed in M. smegmatis. This
drug inhibition. In this view, the major mechanism of
resistance is the overproduction of the high-affinity but l o host strain is modified by inactivation of its endogenous ddl
dispensable target, while the bactericidal effect is due to the
gene, so that it only expresses the M. tuberculosis counterinhibition of the low-affinity lethal target. Our studies do not
part. The M. tuberculosis Ddl enzyme is purified as a
rule out the possibility that the bactericidal action of DCS
polyhistidine-tagged fusion protein through a single-step
affinity chromatography in large amount and its identity is
may result from the inhibition of a lethal target(s) other than
Ddl. Further research is necessary to assess the lethal targets 1s verified with biochemical methods. Ddl catalyzes the reacThus
in the D-alanine branch of peptidoglycan biosynthesis in
tion 2 D-alanine+ATP+o-alanyl-D-alanine+ADP+Pi.
mycobacteria. This information is necessary for the develthe purified protein may be used in any of a variety of in
opment of new antimycobacterial agents targeting the D-alavitro cell-free screen systems as are known in the art.
nine pathway.
The thin-layer chromatography (TLC)-based D-alanine
The practice of the present invention employs, unless 20 ligase assay described in Example 1 can be used, however
otherwise indicated, conventional techniques of chemistry,
it is time consuming and cumbersome, and not readily
molecular biology, microbiology, recombinant DNA and
adaptable to microplate format suitable for high-throughput
screen. A preferred assay is the phosphate release assay
genetics. See, e.g., Maniatis et al. (1982); Sambrook et al.
(1989); Ausubel et al. (1992); Guthrie and Fink (1991);
(such as that used in Piper Phosphate Assay Kit from
Weissbach and Weissbach (1986); Zaitlin et al. (1985) and 25 Molecular Probes) which offers high sensitivity and extraorGelvin et al. (1990).
dinary adaptability. The establishment of such an assay
Method of Use: Drug Susceptibility Assays
permits the screening of thousands of compounds, including,
The bactericidal activity of lead compounds are evaluated
but not limited to, D-cycloserineand modified or derivative
in vitro. Conventional protocols for determination of drug
D-cycloserinemolecules, for potential inhibitors of D-alanine
minimum inhibitorv concentration (MIC)
,
, mav
, be used. 30 ligase.
u
Example ID. employs one example of such assays. For
Promising candidate antimycobacterial agents are further
example, the mycobacterial cells taken from glycerol stock,
tested in vitro using M. smegmatis and M. tuberculosis
or preferably from a single colony, are grown in either
reference strains (See Methods of Use: Drug Susceptibility
Assays). Preferably, the overproducing strains of the present
M-ADC-TW (for faster growing strains such as M. smegmatis) or MO-ADC-TW (for slow growing strains such as 35 invention are used at this step to evaluate the potential
M. avium or M. bovis BCG). Growth is continued in the
bactericidal activity of the lead compounds compared with
absence of test compound until the optical density of 600 nm
D-cycloserine.In addition, the susceptibility of the reference
reaches approximately 0.1 to 1.O. Medium is supplemented
strains to lead compounds indicate the specific pathway or
with nutrients, if necessary.
enzyme targeted.
Method of Use: Analvsis of Drug
Action
Avvroximatelv lo5 CFU in 0.1 ml are inoculated in 40
u
triplicate onto 96-well microplates containing either serial
According to the present invention a method is provided
twofold dilutions of the test compound or without, for
for analyzing the in vivo metabolic change in mycobacteria
upon drug treatment. The free amino acid pool is indicative
controls. Plates are incubated at 37' C. and checked periodically for growth. MIC is determined as the lowest conof the pathways which are either shut down or activated by
In addition. the alteration of free amino acid
centration at which there is no visible ugrowth of bacteria. 45 the test drug.
u
MIC is confirmed by consistent results from at least three
pool, especially the abundance of L- or D-stereotype of an
independent cultures.
individual amino acid, reflect the mode of action of the drug.
Alternatively, the bactericidal activity of the test comThis method is useful compared with cumbersome biopound can be evaluated by measuring D-lactate dehydrogechemical characterization of various bacterial components,
nase activity present in the supernatant. D-lactate dehydro- 50 such as cell wall analysis and lipid analysis. Previously,
genase is a bacterial cytosolic enzyme, and it is only released
amino acid analysis has been used as a tool to determine the
to medium after bacterial lysis. D-lactate dehydrogenase
composition of purified protein or just simply quantify the
amino acid level in biological fluids, however its use has not
detection kits are commercially available and can be adapted
previously been reported for analysis of drug action.
easily to microplate format.
55
Method of Use: Vaccine Development
Method of Use: Inhibition Assays
The present invention is also useful for the development
The present invention is based on the evidence, reported
of a novel vaccine against pathogenic mycobacteria, such as,
in further detail herein: 1) that Ddl is a binding target of DCS
but not limited to, M. tuberculosis, M. bovis, M. africanum,
and is inhibited in a concentration-dependentmanner; 2) that
M. microti, M. leprae, M. avium, M. intracellular, M.
Ddl is not significantly affected by DCS at the concentration
that inhibits Alr; 3) that Alr overproduction contributes to 60 paratuberculosis, M. ulcerans, M. marinum, and subspecies
the maintenance of the internal D-alaninepool, thus antagoand genetic variants thereof. A mycobacteria can be attenunizing the inhibition of Ddl by DCS; and 4) that a strain
ated by selection of mutants that are better suited to growth
overexpressing alr and ddl genes displays increased level of
in abnormal culture conditions and are therefore less capable
resistance to DCS as compared to a strain overexpressing
of growth in the host. The attenuated mycobacterium may
only the alr gene. These results, in view of previously 65 have inserted therein one or more DNA molecules for
reported results, indicate that Alr is a high-affinity but
stimulation of an immune response directed against
dispensable target of DCS, while Ddl is the low-affinity
polypepticles encoded by the inserted nucleic acid molecule.

..

Vaccines of the present invention may be formulated with
conventional carriers andlor adjuvants.
For obvious practical and moral reasons, initial work in
humans to determine the efficacy o experimental compositions with regard to such afflictions is infeasible. Accordingly, in the early development of any drug or vaccine it is
standard procedure to employ appropriate animal models for
reasons of safety and expense. The success of implementing
laboratory animal models is predicted on the understanding
that immunogenic epitopes are frequently active in different
host species. Thus, an immunogenic determinant in one
species, for example a rodent or guinea pig, will generally be
immunoreactive in a different species such as in humans.
Only after the appropriate animal models are sufficiently
developed will clinical trials in humans be carried out to
further demonstrate the safety and efficacy of a vaccine in
man.
With regard
Or pulmonary
M.
tuberculosis, the guinea pig model
the
human pathology of the disease in many respects. Accordingly, it is well understood by those skilled in the art that it
is appropriate to extrapolate the guinea pig model of this
disease to humans and other mammals. As with humans,
guinea vigs are suscevtible to tubercular infection with low
doses of the aerosolized human pathogen M. tuberculosis.
Unlike humans where the initial infection is usually controlled, guinea pigs consistently develop disseminated disease upon exposure to the aerosolized pathogen, facilitating
subsequent analysis. Further, both guinea pigs and humans
display cutaneous delayed-type hypersensitivity reactions
characterized by the development of a dense mononuclear
cell induration or rigid area at the skin test site. Finally, the
characteristic tubercular lesions of humans and guinea pigs
exhibit similar morphology including the presence of Langhans giant cells. As guinea pigs are more susceptible to
initial infection and progression of the disease than humans,
any protection conferred in experiments using this animal
model provides a strong indication that the same protective
immunity may be generated in man or other less susceptible
mammals. Those skilled in the art will appreciate that the
present invention may be practiced with various mammalian
hosts including humans and domesticated animals.
A strain of mycobacteria having a regulatable promoter to
control the expression of the ddl gene, whose product is
responsible for the synthesis of D-alanyl-D-alanine, will
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provide a attenuation of the mycobacterial strain. Use of a
promoter that is active in vitro but is inactive, or minimally
active, in vivo will cause lysis of the mycobacterial cells and
release of immunogens which generate an immunological
response. Replacement of the chromosomal wild type ddl
gene with a regulatable ddl gene can be accomplished by
means known in the art, including the use of a conventional
integrating vector such as those described herein (See
Example 1).
The mycobacterial strain used may be a wild-type mycobacterial strain or, alternatively, an alr null mutant mycobacterial may be used, such as the alr mutant described in
Appl'n Ser, NO. U.S. 2003/0133952.
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EXAMPLE 1
The present invention is further described in the following
examples, which are offered by way of illustration and are
not intended to limit the invention in any manner, Standard
techniques known in the art or the techniques specifically
described below are utilized,
Materials and Methods
A. Bacterial Strains, Plasmids, and Culture Conditions
Bacterial strains and plasmids used in this example are
listed in Table 1. E. coli strains were grown at 37' C. in
Luria-Bertani broth or agar. M. smegmatis strains were
grown at 37' C. with shaking (200 rpm; Innova 4300
incubator shaker; New Brunswick Scientific, Edism, N.J.) in
Middlebrook 7H9 broth (BBL Microbiology Systems,
Cockeysville, Md.) supplemented with albumin-dextrose
complex (ADC) and 0.05% Tween 80 (M-ADC-TW broth).
For analysis of the intracellular amino acid pools, M. smegmatis was grown in a minimal medium based on the formulation of Zygmunt (1963) and modified as previously
described (Chacon et al., 2002). Tryptic soy agar base (Difco
Laboratories, Detroit, Mich.) was used for growth of M.
smegmatis on solid media. Transformations of E. coli and M.
smegmatis were performed by electroporation with a Gene
Pulser (Bio-Rad Laboratories, Richmond, Calif.) as
described previously (Foley-Thomas et al., 1995). The following antibiotics were added to the media when necessary:
kanamycin (Sigma Chemical Co., St. Louis, Mo.) at 50 pg
ml-' or carbenicillin (Sigma) at 50 pg ml-' forE. coli strains
and kanamycin at 10 pg ml-' for M. smegmatis strains.
TABLE 1
Strains and plasmids used in this study

Strain or
plasmid

E. coli XL10GOLD

M. smegmatis
mc2155
M. smegmatis
GPM2
M. smegmatis
GPM14
M. smegmatis
GPM259
M. smegmatis
GPM260
M. smegmatis
GPM265

Description
Tef A(mcrA)183 A (mcrCB-hsdSMR-mrr)l73 endAl
supE44 thi-1 recAl gyrA96
relAl lac Hte [F' proAB lacqZ AM15 TnlO (Tef)
Amy cam7
High-transformation M. smegmatis mutant derived
from mc26
mc2155(p~v262)
DCS-resistant mutant derived from mc2155;
overproducing Alr
mc2155(p~UN250);overproducing Ddl

Reference
andlor
source
Stratagene

Snapper et
al., 1990
Caceres et
al., 1997
5
This work

GPM14(pBUN250); overproducing both Alr and Ddl

This work

mc2155(p~UN276);overproducing M. tuberculosis
Ddl

This work

11
TABLE 1-continued
Strains and plasmids used in this study

Strain or
plasmid

M. smegmatis
GPM198A
pCR2.1
pMV262

Description

Reference
andlor
source
This work

TA cloning vector
E. coli-Mycobacterium shuttle plasmid

Invitrogen
MedImmune,
Inc.;
pMV262 with a 1.4-kb insert containing the complete This work
M. tuberculosis ddl gene
inserted at the EcoRI site
Recombinant plasmid isolated from an M. smegmatis This work
genomic library which
hybridized with an internal fragment of the ddl gene
pMV262 with a 1.4-kb insert containing the complete This work
M. smegmatis ddl gene
inserted at the EcoRI site
pMV262 with the M. tuberculosis ddl gene inserted at This work
the BamHIIHindIII
site; the M. tuberculosis ddl gene is fused with the
DNA sequence
corresponding to the first 6 codons of the M. bovis
BCG hsp60 gene

B. Oligonucleotide primers, nucleic acid manipulations,
library construction, chromosomal DNA was partially
and primer extension analysis.
digested with Sau3A1, and fragments of 3.0 to 4.0 kb were
All oligonucleotide primers were from Integrated DNA
purified from 0.8% agarose. This fraction was ligated with
shuttle plasmid pMV262 (ConTechnologies, Inc., Coralville, Iowa. For PCR amplification 30 the E. co~i-~ycobacterium
of the complete ddl gene from M. smegmatis were SMDnell et al., 1993), linearized with BamHI, and dephosphoDLCF (5'-CGC ATA AGG CCA GGT CAG3'(SEQ ID
rylated. The ligation mixture was transformed into E. coli
and SMDDLCR (5'-CGA AAA ACC CGT CGT
XL10-GOLD (Stratagene, La Jolla, Calif.), and approxiGC-3'(SEQ ID NO:2). The primers for PCR amplification of
mately 6,000 recombinants were obtained for a theoretical
the ddl gene from M.
were DDLATBU (5'-GCT 35 representation of p as >99% of the M, smegmatis genome,
AAG TGC CGA TCG CAA G-3'(SEQ ID NO:3) and
A recombinant clone carrying the M. smegmatis ddl gene
DDLATBD (5f-ATAACG CTG CTG CTG GGT C-3f(SEQ
was identified from a genomic library by colony hybridizaID NO:4) and TBDDLEXF (5t-CGG GAT CCG TGA GTG
tion using a species-specific probe. An internal fragment of
CTA ACG AC3t(SEQ ~ 0 ~ and
5 )TBDDLEXR (5t-CGG
AAG CTT GTG CCG ATC GCA AGC-~~(SEQ
ID ~ 0 ~ 6 40) . the M. smegmatis ddl gene was amplified by PCR using a
~h~ primers SMDDLPE (51-AAA CGC TCC GGA TCG
pair of degenerate primers, DDLF and DDLR, based on two
AGG TTG3'(SEQ ID NO:7) and TBDDLpE (5I-GAG ATG
signature peptides of bacterial Ddl enzymes (Dutka-Malen
GCG TGC TCG TTG-3'(SEQ ID NO:8) were used in primer
et al., 1992). This amplified fragment was verified and
extension analysis for the ddl mRNA of M. smegmatis and
radiolabeled with the Rediprime I1 labeling system (AmerM. tuberculosis, respectively. PCR amplifications were per- 45 sham Pharmacia Biotech, Piscataway, N.J.). For screening
formed in a Perkin-Elmer GeneAmp 9600 thermal cycler
the library, about 10,000 colonies from the library pool were
(Roche Molecular Systems, Branchburg, N.J.) by using the
plated, transferred to the NYTRAN nylon membrane (MidExpand high-fidelity PCR system (Roche hfolecular Biowest Scientific, Valley Park, Mo.), and screened with the
labeled probe as described previously (sambrook et al,,
chemicals, Indianapolis, Ind.). For restriction digestions,
ligations, and agarose gel electrophoresis, standard Proce- 50 1989). After three rounds of screening, the recombinant
dures previously described (SambrOOk et al., 1989) were
plasmid pBUN172 was identified and
to contain
followed. Total RNAfrom M. smegmatis strains was isolated
the full-length ddl gene, This sequence is identical to the
using RNAWIZ (AmbiOn,Inc., Austin, Tex.) with
sequence at GenBa& with accession no, AF077728 (Bemodifications (Bashyam and Tyagi, 1994). Primer extension
langer et al., 2000) and the sequence from the unfinished M.
analysis of the ddl mRNA was carried out as described 55
""'egmatix mc2c'155genome [(J. Craig Center 1nstitute)l.
previously (Davis et al,, 1994). The oligonucleotide was
D. Drug Susceptibility Assays.
radiolabeled with [ y - 3 2 ~by] using
~ ~ ~T4 polynucleotide
kinase (Promega, Madison, Wis.), and the reactions were
MICs were determined by a microdilution method
extended with Moloney murine leukemia virus reverse trandescribed previously (Takiff et al., 1996) with minor modiscriptase (Promega). Radioactivity in primer extension prod- 60 fications. Briefly, M. smegmatis cells were grown in
ucts was quantified with a Phosphorlmager by using
M-ADC-TW to mid-exponential phase (optical density at
ImageQuant, version 3.3 (Molecular Dynamics, Sunnyvale,
600 nm, 0.6 to 1.0). Approximately lo5 CFU in 0.1 ml were
Calif.).
inoculated in triplicate onto 96-well microplates containing
C. M. smegmatis genomic library construction and clonserial twofold dilutions of inhibitory compounds. Plates
ing of the M. smegmatis ddl gene.
65 were incubated at 37' C. and examined daily. The MIC was
defined as the minimal concentration of the drug or inhibitor
Chromosomal DNA from M. smegmatis mc2155 was
prepared as described previously (Whipple et al., 1987). For
that prevented visible bacterial growth after 48 h. Each MIC
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represents the consistent result from at least three independent cultures. Amikacin, DCS, OCDA, ethambutol, and
vancomycin (all from Sigma) were prepared in sterile deionized water. Rifabutin (Amersham Pharmacia) was prepared
in dimethyl sulfoxide (Fisher Scientific, St. Louis, Mo.). All 5
further dilutions of each antibiotic were prepared in growth
medium. Inhibition of colony formation by DCS was evaluated as described previously in Caceres et al., (1997), which
is incorporated herein by reference. Appropriate dilutions of
exponentially growing M. smegmatis cells were plated onto 10
agar containing 0 to 1,200 pg of DCS ml-l. Colonies were
counted after 5 days of incubation at 37' C. Statistical
analysis was conducted using the SAS general linear model
procedure (SAS Institute, Cary, N.C.).
E. Preparation of Crude Cell Extracts from M. smegmatis 15
Strains.
M. smegmatis cells were harvested at exponential phase
and concentrated 50-fold in ice-cold 50 m~ T ~ ~ ~ -( Hp c ~~
8.0). cells were disrupted with a ~~~~~h
cell
(Them0 Spectronic US, Rochester, N.Y.) at 14,000 lb/in2. 20
~h~ lysate was centrifuged at 40 C, for 30 min at 30,000xg
to remove cell debris, ~h~
was subjected to
ultracentrifugation at 40 C, for 4 h at 1 1 0 , 0 0 0 ~
to~remove
the membrane fraction. The recovered supernatant was
dialyzed twice against 50 m~ T ~ ~ ~ -( Hp c8.0)
~~ at 40 C, and 25
sterilized by filtration through 0.22-pm-poresize filters. The
protein concentration was determined by using the DC
protein assay (Bio-Rad) as recommended by the manufacturer.
30
F. Enzyme Assays.
The crude extract was assayed for Ddl activity by a
modified thin-la~er
(TLC)-based method
described previously
and Wright, 1998). This
procedure can quantitatively determine the amount Of D-ala- 35
di~e~tide.
crude extracts (5 to 30 pg
Of
protein) were incubated at 370 C. for
in a 5 0 - ~ 1
'Ontaining 50 mM Tris-HC1 (pH 7.8), l o mM
MgC12, 10 mM KCl, 50 mM unlabeled o-alanine, 6 mM
2'5 mM glutathione>and 5'0 pCi Of [1-14ClD-a1anine 40
(100 pCi/ml; ICN Biochemicals, Inc., Costa Mesa, Calif.).
For inhibition assays, DCS was added to the final concentrations Of 50, loo, 200, 400, and
pg ml-l.
10 p1 of the reaction mixture was applied to cellulose-backed
TLC plates (Sigma), and ascending
was 45
developed in n-butanol-acetic acid-water (12:3:5) until the
solvent reached the top of the TLC plate. The plate was dried
at 100" C. for 5 min, and the radioactivity corresponding to
the position of the D-alanine and D-alanine:D-alanine dipeptide was measured with a Phos~horlmager''pecific
50
was calculated as micromoles of D-alanine consumed per
per minute. The
racemase activity was
measured in the direction of the conversion of L-alanine to
o-alanine by a coupled s~ectro~hotometric
method (Wijsman, 1972) with modifications ('hacon et
2002). 'pe- 55
cific activity was calculated as described previously (Caceres et al., 1997).
G. Analysis of Intracellular Pools of Amino Acids.
M. smegmatis cells were grown in minimal medium until
exponential phase and split into two subcultures, and DCS 60
was added to a final concentration of 75 pg ml-l to one of
the subcultures. After 2 h of incubation, cells were harvested
at 4" C. by centrifugation, washed twice with ice-cold
double-distilled water, and concentrated 50-fold. Cells were
sonicated in a salt-ice-water bath with a Vibra-Cell model 65
VC600 sonicator (Sonic and Materials, Inc., Danbury,
Conn.) for 10 min at 80% power output and 50% duty cycle.

14
The lysate was centrifuged at 4' C. for 30 min at 30,000xg
to remove bacterial debris. Protein was removed from the
supernatant by serial passages through YM-10 and YM-3
Centricon concentrators (Millipore Corp., Bedford, Mass.).
Determination of the abundance of individual amino acids
was performed at the Amino Acid Geochronology Laboratory of Northern Arizona University (Flagstaff, Ariz.) by a
reverse-phase high-performance liquid chromatography
(HPLC) procedure described previously (Kaufman and
Manley, 1998). This procedure is able to detect nine pairs of
L- and D-amino acids in the subpicomole range. For each
sample, the area of the peak representing L-glutamate constituted 50 to 60% of the total area. Thus, the abundance of
each amino acid was calculated as the area under the
corresponding peak and expressed relative to this pool.
H. Overproduction and Purification of M. tuberculosis
Ddl
Introduction. The development of assays to screen for and
characterize novel inhibitors of the M. tuberculosis Ddl
emyme requires large amounts Of purified protein.
a preliminary biochemical characterization of inhibitors
could be undertaken with crude cell extracts from M. tuberculosis, a more thorough analysis of biochemical parameters
require purified products. Furthermore, large amounts Of the
purified protein are required for crystallographic studies.
One P
~ is to purify
~
the~ protein ~
~from M. ~
tuberculosis cell extracts. However, the purification yield is
low, necessitating large cultures of a serious human pathogen. Fortunately, recombinant DNA technology provides the
means to produce large amount of recombinant products
using hosts such as Escherichia coli, which are safe to
handle, and easy to grow and manipulate genetically. In
general, the E, coli system is able to synthesize the proper
mycobacterial protein; however, this is confirmed for the
protein of interest, The M, tuberculosis Ddl in E, coli is
designated herein as r-Ddl, The corresponding biochemical
properties of the native M, tuberculosis Ddl are compared
with those of i--Ddl, The purify proteins are used to determine basic biochemical parameters including the inhibitory
for the well-known inhibitor DCS and derivatives thereof,
Likewise, the determination of biochemical
are performed as a means to compare the properties of r-Ddl
and the native
as well as to
the values
obtained in our study with those previously reported in
classic studies of mycobacteria (David et al,, 1969) and
other microbial systems,
Experimental design, The M, tuberculosis ddl gene is
subcloned into an E, coli overexpression vector, so that a
polyhistidine-tagged Ddl protein is synthesized by the E,
coli recombinant clone, The fusion protein is purified from
E, coli Ddl and other endogenous components by one-step
chromatography based on the properties of the
histidine tag. ~
~
lremoval
l
~of polyhistidine,
~
i
~ poly~
clonal antibodies are raised against the r-Ddl and used to
purify the native M, tuberculosis Ddl from semi-purified
extracts. Using biochemical assays, the kinetic parameters of
V,,,
K, for D-alanine, and K, for DCS for both r-Ddl and
native Ddl, are measured.
To obtain large amount of M. tuberculosis Ddl enzyme,
the ddl gene is PCR amplified based on the genome
sequence and cloned into an E. coli expression vector to
achieve a high level of expression. Preferably, the commercially available PET system (Novagen) is used. The advantage of this system is that the inserted gene will be under the
control of the strong T7 promoter, allowing large quantities
of protein to be produced. In the PET system, the T7 RNA

~

~
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polymerase gene BL21 (DE3), and is itself under the control
of the lac promoter. In the presence of the inducer IPTG, T7
RNA polymerase is expressed and will initiate transcription
of the ddl gene located in the plasmid. The M. tuberculosis
ddl gene is expressed as a fusion protein with a poly-His tag
at either the N- or C-terminus, for use in purification of the
resulting protein by a single-step affinity chromatography.
After optimization of protein expression, a large-scale
experiment is performed to obtain milligram levels of purified protein. The purity and identity of the recombinant Ddl
protein is verified by two-dimensional SDS-PAGE, mass
spectroscopy and N-terminal sequencing, based on the
deduced protein sequence and computer-predicted characteristics, including molecular weight and isoelectric point.
Primers for the M. tuberculosis ddl gene are designed so
that the 5' ends contain the proper restriction enzyme sites to
facilitate cloning. These restriction sites will be chosen using
the following criteria: the sites are not present in the ddl
gene; and they will produce an in-frame fusion with the His
tag in the vector after cloning. Thermostable high-fidelity
DNA polymerase is used to amplify the ddl gene from M.
tuberculosis genomic DNA. The resulting PCR produce is
then digested with the appropriate restriction enzymes and
cloned into PET 15b following standard cloning procedures.
Restriction digestion analysis and DNA sequencing of the
insertional junctions is performed to ensure the correct
in-frame fusion. After verification, the plasmid is transformed into E. coli BL21 (DE3), which carries the T7 RNA
polymerase gene under the control of the lac promoter.
Protein expression is induced by adding 1 mM IPTG to
cultures of recombinant E. coli when the OD600 is between
0.5 and 1.0. Cells are harvested at various time points after
induction and whole-cell crude extracts are analyzed by
SDS-PAGE to detect the expression of the Ddl protein.
Optimal conditions for protein production are obtained from
small-scale analysis of variations in initial culture density,
inducer concentration, growth temperature, agitation speed
and cell density at harvest. Optimized conditions are
adopted for large-scale preparation. Cells are lysed by
French Press and the resulting cell lysate passed through a
Ni affinity column. Recombinant protein with the His tag
bound to the column is eluted and the process repeated until
the protein is purified close to homogeneity. The His tag in
the recombinant protein is cleaved by thrombin prior to
analysis. The purity and identity of the recombinant protein
is confirmed by 2-D SDS-PAGE, mass spectrometry and
N-terminal sequencing.
Purification of M. tuberculosis native Ddl protein. The
Ddl from E. coli and M. tuberculosis is purified to determine
the identity of the recombinant and native proteins. Given
the cytoplasmic localization of the Ddl enzyme, we plan to
prepare crude cell extracts of M. tuberculosis H37Rv are
prepared and the cytosolic fractions are separated as
described above for M. smegmatis. If necessary, further
partial purification of this crude cell extract is performed by
treating the cytosolic fraction with 0.3 mg of RNase and 0.3
mg of DNase, followed by centrifugation at 100,000xg for
2 h at 4" C. in a Beckman Ultracentrifuge by using a Ti 40
rotor. To the precooled new supematant fraction, distilled
acetone is added to precipitate the lipopolyssacharide-like
components. The supernatant of the acetone precipitation is
centrifuged a 100,000xg for one hour to precipitate proteins.
The pellet is redissolved in buffer, and the Ddl protein is
further purified by affinity chromatography using the polyclonal antibodies raised against the purified r-Ddl. Most of
these steps are similar to those described in the classic
studies of the M. tuberculosis Ddl by David et al. (1969),

except for the last affinity chromatography step. Altematively, the crude cell-free extract will be concentrated and
loaded on the affinity chromatography column, without
additional purification steps.
Determination of kinetic parameters. Using both the TLC
and the P, release assay, the type of inhibition and the
corresponding kinetic parameters are determined. The V,,,
K, and K, for DCS will be evaluated by the double reciprocal plot method. Preferably, the Pi assay is used because
it is readily adaptable to a high throughput screen procedure.
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Overexpression of the M. smegmatis and M.
tuberculosis ddl Genes in Recombinant M.
smegmatis.
The M. smegmatis ddl gene was isolated from a genomic
library as described in Example 1. The DNA fragment
containing the ddl gene coding sequence, including 190 bp
of the 5' flanking region and 35 bp of the 3' flanking region,
was amplified by PCR and ligated into the EcoRI site of
pMV262 to generate pBUN250. This plasmid was electroporated into M. smegmatis mc2155, yielding GPM259.
Since pMV262 is present in M. smegmatis at 5 to 10 copies
(Caceres et al., 1997), the ddl gene is expected to be
overexpressed in the recombinant M. smegmatis strain due
to a gene dosage effect. This was confirmed by primer
extension analysis using total RNA isolated from mc2155
and GPM259. Radiometric quantitation of the primer extension bands confirmed that GPM259 overproduced the ddl
transcript by 25-fold compared to mc2155. In both samples,
two transcriptional start sites were detected, one immediately upstream and another 3 nucleotides upstream of the
start codon (GTG) (FIG. 1A). Further analysis of the
sequence immediately adjacent to the start codon did not
reveal any significant RNA secondary structures, excluding
the possibility that the two bands detected were the result of
premature extension products. It has been found for the
Mycobacterium fortuitum blaF (Timm et al., 1994) and 11
streptomycete genes (Strohl, 1992) that transcription start
sites are extremely close to the start codon. This may suggest
that translation initiation in both mycobacteria and streptomycetes has less-stringent requirements for the recognition
of a ribosome-binding site.
Following the same strategy, we constructed an M. smegmatis recombinant strain, GPM19XA, carrying the plasmid
pBUN12XA, a pMV262-based plasmid containing the M.
tuberculosis ddl gene coding sequence, including 140 bp of
the 5' flanking region and 130 bp of the 3' flanking region.
Total RNA isolated from GPMl9XA was subjected to primer
extension analysis using oligonucleotides specific to either
the M. smegmatis or the M. tuberculosis ddl gene. The
results revealed that this strain overexpressed the endogenous M. smegmatis ddl gene rather than the plasmid-carried
M. tuberculosis ddl gene. To circumvent this problem, a
different strategy was followed. Briefly, the M. tuberculosis
ddl gene was amplified by PCR and cloned into pMV262,
yielding pBUN276. In this construct, the M. tuberculosis ddl
gene is fused in frame with the first six codons of the
Mycobacterium bovis BCG hsp60 gene and is under the
control of its promoter. Total RNA isolated from the corresponding recombinant strain, GPM265, was subjected to
primer extension analysis as described above. In this case,
the chromosomally encoded ddl gene in GPM265 was
expressed at a level similar to the level in wild-type mc2155
(FIG. lA), while the episomal M. tuberculosis ddl gene was
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expressed at an approximately 30-fold-higher level than the
chromosomally encoded ddl gene (FIG. 1B). The transcriptional start site of the M. tuberculosis ddl gene located on
pBUN276 was identified as the G nucleotide located 183 bp
upstream of the start codon of the hsp60 gene, consistent
with previous observations (Stover et al., 1991). As
expected, no M. tuberculosis ddl transcript was detected
from mc2155 or GPM259 total RNA.

18

DCS for mc2155, GPM259, GPM265, and GPM14 were
determined (Table 2). GPM14, overproducing Alr, is a
spontaneous DCS-resistant mutant derived from mc2155
(Caceres et al., 1997). The MICs of DCS for strains
5 GPM259 and GPM265 (both at 150 pg ml-l) were twofold
greater than that for mc2155 (75 pg ml-l) but were lower
than that for GPM14 (300 pg ml-l). Thus, recombinant
strains overproducing Ddl showed increased levels of resistance to DCS but were not as resistant as the Alr-overproEXAMPLE 3
l o ducing strain GPM14. The susceptibilities of these strains to
13CDA, which interferes with the incorporation of D-alanine
Enzymatic Characterization of M. smegmatis
into the bacterial cell wall, were also determined (Table 2).
Strains
BCDA, an analog of D-alanine, was reported to target
bacterial alanine racemases and transaminases (Manning et
The overexpression of the M. smegmatis or M. tubercu- 1s al., 1974) and showed a synergistic effect with DCS against
losis ddl gene was further confirmed by measuring Ddl
M. tuberculosis (David, 2001). In this study, only the strain
enzyme activities. For this, Ddl-specific activities in cell
overproducing Alr showed increased resistance to BCDA, as
crude extracts from mc2155, GPM259, and GPM265 were
the MIC for GPM14, 100 pg ml-l, is fourfold higher than
determined by the TLC-based method described in Example
those for other strains with wild-type levels of Alr. These
1. A typical autoradiogram of the TLC-based Ddl enzyme 20 data are consistent with the mode of action of OCDA, which
inhibits the Alr enzyme. In addition, susceptibilities to other
assays for strain GPM259 is shown in FIG. 2A. Ddl-specific
antimicrobial agents targeting cell wall biosynthesis (ethamactivities in crude extracts from GPM259 and GPM265 were
about 35 and 30 times greater, respectively, than that in
butol and vancomycin), RNA synthesis (rifabutin, a strucmc2155 extracts (FIG. 3A). These increases in Ddl activity
tural analog of rifampin with higher antimycobacterial activwere consistent with the primer extension results. As a 25 ity), and protein synthesis (amikacin) of these M. smegmatis
control, Alr enzyme activities were concurrently determined
strains were identical. The DCS resistance phenotype of the
by a coupled spectrophotometric method as described in
Ddl-overproducing strains was further confirmed by plating
Materials and Methods. As expected, cell crude extracts
bacteria on solid agar containing various concentrations of
DCS. Consistent with the MIC data, GPM259 and GPM265
from mc2155, GPM259, and GPM265 displayed similar Alr
activities (FIG. 3B), indicating that overexpression of the 30 are more resistant to DCS than the wild-type mc2155 but less
ddl gene is specific and does not alter the expression of the
resistant than the Alr-overproducing strain GPM14 (FIG. 5).
alr gene. Furthermore, there were no observed differences
Furthermore, this type of intermediate level of resistance to
between the recombinant strains overproducing Ddl and the
DCS is not related to Alr, since crude extracts from both
GPM259 and GPM265 contained a wild-type level of Alr
wild-type strain regarding growth rate, growth saturation
density, and colony morphology, indicating that the overex- 35 activity (FIG. 3B). Therefore, overproduction of the Ddl
pression of the ddl gene is not toxic to the host.
enzymes leads to a DCS resistance phenotype in M. smegPreviously, David et al. (1969) reported that DCS commatis. However, this level of resistance may not suffice for
selection of DCS-resistant clones by following the strategy
petitively inhibits the M. tuberculosis Ddl enzyme. In this
study, we performed in vitro inhibition assays to determine
described above.
the Ddl-specific activities of crude extracts from mc2155, 40
EXAMPLE 5
GPM259, and GPM265 in the presence of increasing concentrations of DCS. A typical autoradiogram of the inhibiConstruction and Characterization of an
tion assay for the crude extract of GPM259 is shown in FIG.
Alr-Ddl-overproducing Mycobacterial Strain
2B. The degree of inhibition for the Ddl activities in these
extracts increased proportionally to the DCS concentration 45
(FIG. 4). No statistically significant differences between the
It has been reported previously that a specific type of
DCS-resistant Streptococcus gordonii mutants displayed
extracts from mc2155 and GPM259 were observed. Howelevated Alr and Ddl activities and that the level of resisever, though the inhibition of the Ddl activity in GPM265
crude extract followed a similar pattern, the percentage of
tance to DCS is higher than that for mutants with elevated
inhibition was approximately 10% higher at each concen- 50 Alr activity only (Reitz et al., 1967). To test the effect of the
tration of DCS (Pe0.02). Since the primer extension analysis
overproduction of both Alr and Ddl in M. smegmatis on DCS
indicated that more than 95% of the Ddl activity present in
susceptibility, we introduced the multicopy plasmid
the crude extract of GPM265 is from the expression of the
pBUN250 carrying the ddl gene into the Alr-overproducing
M. tuberculosis ddl gene, this slight difference may reflect a
strain GPM14. As expected, the resulting strain, GPM260,
moderately higher sensitivity of the M. tuberculosis Ddl 55 overproduced both Alr and Ddl as demonstrated by enzyenzyme to DCS inhibition. In summary, these data indicate
matic characterization (FIG. 3). In addition, the degree of
inhibition of the Ddl activities in extracts from GPM260 and
that both M. smegmatis and M. tuberculosis Ddl enzymes are
inhibited by DCS in a concentration-dependent manner and
its parental strain, GPM14, increased proportionally to the
provide further evidence that Ddl is a target of this drug.
DCS concentration (FIG. 4). No statistically significant
60 differences between these extracts were observed (P>0.28).
EXAMPLE 4
Note that the overproduction of Alr in GPM14 and GPM260
does not alter the degree of in vitro inhibition of the Ddl
Drug Susceptibilities of M. smegmatis Strains
enzyme by DCS. Thus, increasing amounts of Alr protein do
not seem to affect the inhibitory effect of DCS on Ddl
To test whether Ddl overproduction confers a DCS resis- 65 activity. The susceptibilities of GPM260 to OCDA, ethambutol, vancomycin, rifabutin, and amikacin were identical to
tance phenotype, we evaluated the susceptibilities of M.
smegmatis strains overproducing Ddl to DCS. The MICs of
those of the parent strain, GPM14 (Table 2). However,
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GPM260, overproducing both Alr and Ddl, was significantly
more resistant to DCS than the wild-type strain or strains
overproducing only Alr or Ddl (Table 2 and FIG. 5).

D-alanine. The observed decrease of the D-alanine pool is
statistically significant for strains GPM259 (P=0.05),
GPM14 (P=0.01), and GPM260 (PP0.01). For strain
mc2155, the decrease of the D-alanine pool fell below the
statistically significant level (P>O.ll). However, this strain
displayed the maximum accumulation of L-alanine, and the
L-alanine-to-D-alanine molar ratio increased 3.5-fold

TABLE 2

5

MICS of DCS M. smermatis strains

MIC"
Phenotype
Strain

Alr

Ddl

mc2155
GPM2
GPM259
GPM14
GPM260
GPM265

wtC
wt
wt
Overproduced
Overproduced
wt

wt
wt
Overproduced
wt
Overproduced
Overproducedd

(WEml-1)

lo

fiCDA"
25.0
25.0
25.0
25.0

75.0
75.0
150

36:

15

150

"MICs were determined in M-ADC-TW media by a microdilution method
as described in Materials and Methods.
"A chi-square test was performed for MICs obtained from at least four
independent cultures. Susceptibilities to fiCDA can be divided into two
groups (group I, 1112155, GPM2, GPM259, and GPM265; group 11,
GPM14 and GPM260). Significant differences (P < 0.001) between these
two groups were detected, while no significant differences (P 2 0.537)
within each group were detected.
'A chi-square test was performed for MICs obtained from at least seven
independent cultures. Susceptibilities to DCS can be divided into four
groups (group I, 1112155 and GPM2; group 11, GPM259 and GPM265;
group 111, GPM14;
IV, GPM260), Significantdifferences between
these two groups were detected (group I versus group 11, P = 0.001; group
11 versus group 111, P P = 0.001; group IIIversus group VI, P = 0.008),
while no significant differences within each group were detected (group I,
P = 0.881; group 11, P = 0.893).
d ~ o r than
e 95% of the Ddl activity in GPM265 is due to the expression
of the episomal copy of the M. tuberculosis ddl gene (see text).
"wt, wild type.
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EXAMPLE 6
35

Analysis of the Intracellular L- and D-alanine Pools
The incorporation of D-alanine into peptidoglycan
requires the sequential interconversion of L- into D-alanine
followed by the formation of the D-alanine dipeptide, reactions catalyzed by Alr and Ddl, respectively. The interplay
between D-alanine biosynthesis by Alr and its consumption
by Ddl contributes to the determination of the intracellular
level of this amino acid. Inhibition of Alr alone would
decrease the intracellular pool of D-alanine. Therefore, in
live bacilli exposed to sublethal concentrations of DCS (near
the MIC for the wild-type strain), if Alr is inhibited to a
greater extent than Ddl, a decrease in the D-alanine pool
would be expected. To test this hypothesis, we determined
the intracellular alanine pools of mc2155,
GPM14'
GPM259, and GPM260 with and without DCS treatment
a reverse-phase HPLC. This methodology allowed detection
of D- and L-alanine, L-arginine, L-asparaginelaspartate, Dand L-glutaminelglutamate (Glx), glycine, L-isoleucine,
L-leucine, D-phenylalanine, L-serine, and D- and L-valine
from samples prepared from cell extracts as described in
Example 1 (FIG. 6). It was observed that the L-Glx pool was
the most abundant, probably reflecting its crucial role in
nitrogen metabolism. Moreover, this pool displayed no
significant variations upon DCS treatment (P>0.63), so it
was used as a standard to normalize all other intracellular
pools.
Comparison of the amino acid pools in each strain upon
DCS exposure revealed that this treatment had a specific
effect on the intracellular alanine pools (FIG. 7). In all
strains tested, DCS treatment led to a significant accumulation of L-alanine (Pe0.03) and a concomitant decrease of

40

(p~o.01).
The intracellular pools of D- and L-alanine were also
dependent on the steady-state production levels of Alr and
Ddl enzymes. In cells not exposed to DCS, a twofold excess
of the L-stereoisomer was observed for strains mc2155,
GMP259, and GPM 260 (PP0.30) but strain GPM14 displayed almost equimolar amounts of both isomers, a result
significantly different from those for the rest of the strains
(Pe0.01). These data suggest that the overproduction of Alr
favors the maintenance of a relatively abundant pool of
D-alanine, ~
~with DCS~ led to the
~ most significant
t
~
changes, as observed by comparing effects among different
strains. In the wild-type strain mc2155, an eightfold excess
of L- over D-alaninewas observed. In the Alr-overproducing
Strain GPM14, only a three-fold excess was observed,
representing a statistically significant difference from the
wild-type strain (Pe0.02). In contrast, the Ddl-overproducing strains ~ ~ ~ and
2 ~5 ~9 ~ displayed
2 6 0 an 18- to
20-fold excess of L-alanine. This result indicated that there
were no significant differences between GPM259 and
GPM260 (P>O.XO) but that these two strains differed significantly from both the wild-type strain ( ~ ~ 0 . 0 4and
)
GPM14 (PPO.O1).
these changes are
determined by a significant reduction in the D-alanine pool
compared to the values for the wild-type strain mc2155
(PP0.03) and GPM14 (PP0.01). These observations suggest
that, in the Ddl-overproducing strains GPM259 and
GPM260, Ddl is not significantly inhibited by DCS at
concentrations that inhibit Alr. Moreover, the inhibition of
Alr by DCS was quite effective, since the Alr-Ddl-overproducing strain GPM260 displayed values for both the D- and
L-alanine pools similar to those displayed by strain
GPM259, with wild-type Alr levels and overexpression of
DdL.
EXAMPLE 7
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High Throughput Screening of Potential Ddl
Inhibitors
D-alanine ligase (Ddl) activity is determined in a cell-free
phosphate release assay (Piper Phosphate Assay Kit,
Molecular Probes). This assay measures the amount of
inorganic phosphate generated during the production of
D-alanyl-D-alanine, Purified M, tuberculosis Ddl enzyme
(Example 1H.) is used in the assay to reduce background and
increase sensitivity of the assay. The assay is performed
according to manufacturers instructions.
Promising lead drug candidates are further tested in vitro
using reference mycobacterial strains, such as M. smegmatis
and M. tuberculosis Ddl overproducing strains, GPM259,
GPM260, and GPM265, to evaluate the potential mycobactericidal activity of the lead compounds compared to DCS.
EXAMPLE 8
Construction of Live-attenuated Vaccine Against
Mycobacterium tuberculosis

65

Vaccine development starts with virulent M. tuberculosis
microorganisms from which attenuated mutants are gener-

~

~
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ated. These mutants preferably carry at least two attenuating
deletion mutations and no antibiotic resistant markers, so as
to avoid unwanted reversions or transfers of drug-resistance.
Vaccine strains may include one or more additional mutations. The vaccine strain is optionally potentiated by coadministration of cytokines or by endowing the engineered
strain with the capability to produce cytokines or phagosome
membrane disrupters, such as lysteriolysin. Preferably, temporal expression of these genes is regulated by promoters
solely active inside phagocytic cells.
A strain of M. tuberculosis is constructed which is
merodiploid, with an episomal copy of the ddl gene under
the control of a promoter that is not expressed in vivo. The
chromosomal copy of the native ddl gene is inactivated by
means known in the art, such as point mutation or by
addition, deletion, or substitution of one or more base pairs,
preferably by deletion of one or more base pairs. The
resulting strain is able to grow in synthetic medium but is
unable to grow in viva, because ~-alanyl-~-alanine
is not
synthesized. As a result the cells undergo spontaneous lysis,
releasing immunodominant B and T cell antigens. The strain
may further include inactivation of the air gene and/or may
include genes for recombinant foreign antigens.
Such strains would be useful for the generation of attenuated live-attenuated vaccine candidates against tuberculosis
and other human or animal diseases caused by mycobacteria
such as leprosy, Johne's disease, and possibly Crohn's
disease. Because such strains are impaired in the ability to
synthesize the basic building block of cell walls, peptidoglycan, the strains undergo spontaneous lysis in vivo. Lysis
provides improved antigen delivery and containment of the
vaccine strain.
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The plasmid pBUN276 has been deposited with the
American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209, USA, on Jan.
26, 2007 in accordance with the ~~d~~~~~T~~~~ and have
been accorded accession number PTA-8190.
From the foregoing it will be seen that this invention is
one well adapted to attain all ends and objectives hereinabove set forth, together with the other advantages which are
obvious and which are inherent to the invention.
Since many possible embodiments may be made of the
invention without departing from the scope thereof, is to be
understood that all matters herein set forth or shown in the
accompanying drawings are to be interpreted as illustrative,
and not in a limiting sense.
'pecific embodiments have been shown and discussed, various modifications may of course be made, and
the invention is not limited to the specific forms or arrangement of parts and steps described herein, except insofar as
such limitations are included in the following claims. Further, it will be understood that certain features and subcombinations are of utility and may be employed without
reference to other features and sub-combinations. This is
contemplated by and is within the scope of the claims.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 8
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 1
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial
FEATURE :
OTHER INFORMATION: SMDDLCF PRIMER

<400> SEQUENCE: 1
cgcataaggc caggtcag

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 2
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial
FEATURE :
OTHER INFORMATION: SMDDLCR PRIMER

<400> SEQUENCE: 2
cgaaaaaccc gtcgtgc

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 3
LENGTH: 19
TYPE: DNA
ORGANISM: Artificial
FEATURE :
OTHER INFORMATION: DDLATBU PRIMER

<400> SEQUENCE: 3
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gctaagtgcc gatcgcaag

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 4
LENGTH: 19
TYPE: DNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: DDLATBD PRIMER

<400> SEQUENCE: 4
ataacgctgc tgctgggtc

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 5
LENGTH: 23
TYPE: DNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: TBDDLEXF PRIMER

<400> SEQUENCE: 5
cgggatccgt gagtgctaac gac

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 6
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: TBDDLEXR PRIMER

<400> SEQUENCE: 6
cggaagcttg tgccgatcgc aagc

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 7
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: SMDDLPE PRIMER

<400> SEQUENCE: 7
aaacgctccg gatcgaggtt g

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 8
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: TBDDLPE PRIMER

<400> SEQUENCE: 8
gagatggcgt gctcgttg

What is claimed and desired to be secured by Letters
Patent is as follows:
1.A recombinant plasmid pBUN276 on deposit with the
American Type Culture Collection as accession number
PTA-8190.
2. A transformed microorganism comprising the plasmid
of claim 1.
3. The transformed microorganism of claim 2, wherein the
microorganism is a naturally occurring or genetically modified mycobacterium strain selected from the group consisting of M. smegmatis, M. tuberculosis, M. bovis, M. africanum, M. microti, M. leprae, M. avium, M. intracellular, M.
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paratuberculosis, M. ulcerans, M. marinum, and any subspecies of said mycobacterium strains.
4. The transformed microorganism of claim 2, wherein the
transformed microorganism is recombinant mycobacterium
strain GPM265.
5. A recombinant plasmid, comprising at least one
genomic DNA fragment encoding M. tuberculosis Ddl, said
at least one DNA fragment fused in frame with the first six
codons of M. bovis BCG hsp60 gene, and operably linked to
the promoter of the M. bovis BCG hsp60 gene, wherein said
at least one DNA fragment is cloned into an E. colimycobacterium shuttle vector.
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6. A method for producing a recombinant microorganism
comprising: transforming a mycobacterium with the plasmid
of claim 1,and selecting, in the presence of kanamycin, the
recombinant microorganism.

7. The method of claim 6, wherein the mycobacterium is
transformed by electroporation.
8. Amethod of producing a microorganism with an altered
level of D-alanine ligase expression relative to the corresponding non-transformed microorganism, comprising
transforming the microorganism with the plasmid of claim 1.
9. A method of screening for agents which inhibit D-alanine ligase activity, comprising:
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(a) exposing a culture of the recombinant mycobacterium
strain of claim 4 to an agent to be tested to form a test
culture; and
(b) comparing the D-alanine ligase activity of the test
culture with the D-alanine ligase activity of a control
culture of the recombinant mycobacterium strain of
claim 4 in the absence of the agent,
wherein less D-alanine ligase activity in the test culture
than in the control culture is indicative of inhibition of
D-alanine ligase activity by the agent.
10. The method of claim 9, wherein the agent is an
agent.
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